Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Autor: Jolijn R. van Leeuwen, Obbo W. Bredewold, Laura S. van Dam, Stella L. Werkman, Jacqueline T. Jonker, Miranda Geelhoed, Antonius P.M. Langeveld, Hilde H.F. Remmelts, Maud M. van den Broecke, Argho Ray, Ton J. Rabelink, Y.K. Onno Teng

Publikováno v: Kidney International Reports, Vol 7, Iss 3, Pp 624-628 (2022)

Externí odkaz: https://doaj.org/article/5b3fb8844ccb42a4b56ad3cfd673ea1b

LBO2 Long-term renal and cardiovascular risks of tacrolimus in lupus nephritis patients

Autor: Obbo W Bredewold, Ton J Rabelink, YK Onno Teng, Joris I Rotmans, Mieke van Schaik, Merel Priester, Wieneke M Michels

Publikováno v: Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)

Externí odkaz: https://doaj.org/article/f2f7c07582454c40a4fdfd321aa95ade

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial

Autor: Obbo W. Bredewold, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström

Publikováno v: Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A-J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, Fijter, J W D, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sörensen, S S, van Zonneveld, A J & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574

RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. Our object

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69b94a611d7a310d374c44136f21cf6
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498007

Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial

Autor: Obbo W. Bredewold, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Sören S. Sörensen, Anton-Jan Zonneveld, Bengt Fellstrom

In renal transplant recipients (RTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. The aim of this randomized, multi-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5eac222c1e58682c102b6e3108952dd8
https://doi.org/10.21203/rs.3.rs-1283060/v1

Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients

Autor: Jelle M Oskam, Jacques J.M. van Dongen, Y K Onno Teng, E J Arends, Magdalena A Berkowska, Obbo W. Bredewold, Cees van Kooten, Ton J. Rabelink, Laura S van Dam, Sylvia W.A. Kamerling

Publikováno v: Frontiers in Immunology, 11. FRONTIERS MEDIA SA
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology

BackgroundB-cell depletion with rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients. Nevertheless, relapses are frequent after RTX, often preceded by B-cell repopulation sug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bb34647ec256116e06c3d74c3214c7
https://hdl.handle.net/1887/3184295